Clinical evaluation of [¹⁸F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease.

ABSTRACT:

Purpose

The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer's disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [¹⁸F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer's disease to age-matched healthy controls.

Methods

[¹⁸F] JNJ-64326067 PET scans were acquired for 90 min and then from 120 to 180 min in 5 participants with [¹⁸F]-florbetapir PET amyloid positive probable AD (73 ± 9 years) and 5 [¹⁸F]-florbetapir PET amyloid negative healthy controls (71 ± 7 years). Whole-body [<

SUBMITTER: Schmidt ME 

PROVIDER: S-EPMC7680304 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature